Who is the biggest winner? Analysis of top 50 products with the largest sales growth in 2014

Source: Xinkangjie / Mingming 2015-03-17 recently, firstword released a list of top 50 drugs with global sales growth The total sales of these 50 drugs increased by 37 billion US dollars in 2014, of which the top 10 contributed 22.5 billion US dollars Half of the increase was contributed by harvoni, Gilead's hepatitis C treatment drug In 2014, the drug's sales reached $10.2 billion, becoming the "king of growth" Another hepatitis C treatment drug, olysio, from Johnson & Johnson, ranked second In clinical practice, olysio combined with harvoni to treat hepatitis C, so Johnson & Johnson recorded $2.302 billion in revenue from the drug Each of the top 50 drugs contributed at least $200 million in sales growth In 2014, the top 50 drugs (US $100 million) with the most growth included 14 cancer products (28% of the top 50), the total sales increased by US $52 billion (14% of the top 50) year on year, and Revlimid of celgene increased by US $700 million in sales, leading the field of cancer medicine Next came Royce's perjeta for breast cancer (up $647 million in sales) and Johnson & Johnson's zytiga for prostate cancer (up $539 million in sales) In 2014, imbruvica, a drug used by Johnson & Johnson and pharmacyclics to treat B-cell malignant tumors, ranked 18th in the sales growth ranking, and also ranked fourth in the sales growth of tumors Not long ago, Aberdeen agreed to buy pharmacyclics for $21 billion In the top 50, eight products are biological agents, mainly focusing on rheumatoid arthritis and so on The total sales volume of biological agents increased by 3.9 billion US dollars, almost half of the growth came from the TNF inhibitor Humira of ibuprofen However, the competition for Humira's biological analogues is in Europe, and the sales trend of the drug has reached a critical point In the list, there are four multiple sclerosis products, including tecbidera and Tysabri of bjei, gilenya of Novartis and aubagio of Sanofi The total sales volume of these four products increased by 3.4 billion US dollars, of which tecbidera is the third product with sales growth, and the sales volume increased by 2 billion US dollars last year Despite the increasing pressure of competition, six of them are still used to treat diabetes, with a total sales increase of US $2.3 billion Sanofi's insulin products are the largest growing products in the field of diabetes Despite the pressure of price competition, the French company is on the way to franchising sales Last year, sales increased by $836 million Sales of clotting factor Xa inhibitors continued to grow, including Bayer / Johnson's xarlto and Bristol Myers Squibb / Pfizer's eliquis, with sales up $1.6 billion and $628 million in 2014, respectively In the case of delayed listing expectation, eliquis's performance is remarkable Its competitor in the field of oral anticoagulant, pradaxa, the direct thrombin inhibitor of bringer Ingelheim, is still unknown If it can be compared, it will surprise the market Eylea, the eye treatment drug of Zaiyuan and Bayer, still performed strongly, with sales increasing by $894 million in 2014, mainly benefiting from the new indications approved by FDA in addition to the treatment of wet age-related macular degeneration (AMD) This will undoubtedly bring greater competitive pressure to Novartis / Roche's Lucentis, whose sales growth has slowed down in 2013-2014 There are also four HIV treatment products on the list, with a total sales growth of $1.7 billion Among them, Gilead's franchises include three drugs: stribild, complera and truvada, with sales growth of $1.3 billion, while GSK's tivicay / trimeq franchises increased by $434 million Johnson & Johnson and Roche each have 5 drugs on the top 50 list, while Gilead has 4 drugs Gilead took the lead in sales growth, mainly benefiting from the amazing sales growth of sovaldi Sales of Geely's four products increased by $11.5 billion The total sales of the five products on the list of Johnson & Johnson increased by 4 billion US dollars, while the total sales of Bayer and Baijian Aidi products on the list increased by 250 million US dollars respectively Although the sales growth of some core products is slow (including Avastin and rituximab, which have dropped out of the top 50 list), Roche's products in the top 50 list also have a total sales growth of $1.8 billion Looking forward to the next year, we can foresee that the first PD-1 inhibitor, opdivo of Bristol Myers Squibb (for melanoma and non-small cell lung cancer) and keytruda of mosadon (for melanoma), will appear in this list Although Bristol Myers Squibb's R & D pipeline story is good, due to the unsatisfactory output ratio in 2014, the company has gained $1.4 billion in sales growth from the franchises of eliquis, yevoy, sprycel and orencia Large pharmaceutical companies still dominate the list, with 34 products (68%) coming from large pharmaceutical companies, while 12 products (24%) from biotechnology companies with large market value are on top 50 Alexion and Incyte, mid cap biotech companies, were also lucky to make the list In addition, youshibi also made the list through cimzia, a heavy bomb In addition, there are two Japanese pharmaceutical companies on the list: Astaire and Takeda pharmaceutical